delavirdine has been researched along with zalcitabine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (26.67) | 18.2507 |
2000's | 2 (13.33) | 29.6817 |
2010's | 8 (53.33) | 24.3611 |
2020's | 1 (6.67) | 2.80 |
Authors | Studies |
---|---|
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P | 1 |
Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
Balzarini, J; Chen, W; De Clercq, E; Liu, H; Liu, X; Pannecouque, C; Rai, D; Zhan, P; Zhou, Z | 1 |
Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Chong, KT; Hinshaw, RR; Pagano, PJ | 1 |
Saag, MS; Schooley, RT | 1 |
Temesgen, Z; Wright, AJ | 1 |
Berger, AR; Eng, KT; Liu, ES; Silverman, MS | 1 |
3 review(s) available for delavirdine and zalcitabine
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
12 other study(ies) available for delavirdine and zalcitabine
Article | Year |
---|---|
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
Topics: Aniline Compounds; Cell Line; Chlorine; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2011 |
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication | 2012 |
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines | 2012 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide | 2012 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
Topics: Anti-HIV Agents; Crystallization; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Leukocytes, Mononuclear; Piperazines; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cholesterol; Delavirdine; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Retinal Diseases; Retinal Vessels; Ritonavir; Saquinavir; Triglycerides; Viral Load; Zalcitabine | 2000 |